Share This Page
Investigational Drug Information for Alovudine
✉ Email this page to a colleague
What is the development status for investigational drug Alovudine?
Alovudine is an investigational drug.
There have been 8 clinical trials for Alovudine.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 18th 2020.
The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are National Cancer Institute (NCI), Lederle Laboratories, and Boehringer Ingelheim.
Summary for Alovudine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,505 |
| WIPO Patent Applications | 992 |
| Japanese Patent Applications | 224 |
| Clinical Trial Progress | Phase 2 (2020-02-18) |
| Vendors | 50 |
Recent Clinical Trials for Alovudine
| Title | Sponsor | Phase |
|---|---|---|
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | National Cancer Institute (NCI) | Phase 2 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | National Cancer Institute (NCI) | Early Phase 1 |
Clinical Trial Summary for Alovudine
Top disease conditions for Alovudine
Top clinical trial sponsors for Alovudine
US Patents for Alovudine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Alovudine Development Update and Market Projection
Alovudine is an abandoned investigational nucleoside reverse transcriptase inhibitor for HIV-1 infection. The compound, also known as FLT and MIV-310, has no FDA approval, no marketed product, no Orange Book listing, and no visible active clinical development program. Historical studies showed antiviral activity, including activity against some resistant HIV strains, but development did not progress because the clinical risk-benefit profile was inadequate for commercial HIV treatment.
The current commercial value of alovudine is effectively zero without a new sponsor, redesigned development strategy, or a new indication. Its most plausible value is limited to research use, historical intellectual property, or a potential combination-treatment project.
What is alovudine and how does it work?
Alovudine is a thymidine nucleoside analogue that inhibits HIV reverse transcriptase after intracellular phosphorylation to its active triphosphate form. It causes DNA chain termination during viral replication.
| Attribute | Alovudine |
|---|---|
| Generic name | Alovudine |
| Other names | FLT, MIV-310 |
| Drug class | Nucleoside reverse transcriptase inhibitor |
| Target | HIV-1 reverse transcriptase |
| Chemical type | Fluorinated thymidine analogue |
| Development sponsor historically associated with the compound | Medivir AB |
| FDA status | Not approved |
| EMA status | No marketing authorization identified |
| Market status | Not marketed |
| Biosimilar status | Not applicable |
| Current development status | No active public clinical program identified |
Alovudine was designed to provide potent antiretroviral activity at a time when HIV treatment relied heavily on nucleoside reverse transcriptase inhibitors. Its mechanism overlaps with approved thymidine analogues such as zidovudine, but its development profile raised safety concerns that limited its utility.
PubChem identifies alovudine as a fluorinated nucleoside analogue with the molecular formula C10H13FN2O4 and CAS Registry Number 25526-93-6. (National Center for Biotechnology Information, n.d.)
What is the development status of alovudine?
Alovudine reached early- to mid-stage clinical development in HIV-infected patients but did not advance to registration. Historical development work evaluated antiviral activity, tolerability, resistance characteristics, and use in patients with prior antiretroviral exposure.
Publicly available records do not identify a current sponsor conducting Phase III studies, regulatory-enabling studies, or commercial manufacturing development. The compound is therefore best classified as discontinued clinical-stage research rather than a delayed or active pipeline asset.
Historical development profile
| Development element | Public status |
|---|---|
| Preclinical antiviral testing | Completed |
| Human clinical testing | Conducted |
| Phase II-stage evaluation | Reported historically |
| Phase III program | No evidence of completion |
| New drug application | Not identified |
| FDA approval | None |
| Commercial launch | None |
| Active sponsor | None identified in current public records |
The key development problem was toxicity at exposure levels needed for sustained antiviral treatment. Reports on alovudine identified adverse effects associated with nucleoside analogue toxicity, including concerns involving mitochondrial function and neuromuscular tolerability. These risks were commercially significant because HIV patients require chronic, often lifelong therapy.
Why was alovudine development discontinued?
Alovudine did not achieve a viable development profile against established and emerging HIV therapies. Antiviral potency alone was insufficient. A successful HIV nucleoside must also demonstrate durable tolerability, manageable resistance, compatibility with combination regimens, and a dosing profile that supports long-term adherence.
The principal barriers were:
- Safety concerns associated with chronic exposure.
- Competition from approved nucleoside and non-nucleoside reverse transcriptase inhibitors.
- Rapid expansion of combination antiretroviral therapy.
- The absence of a clear differentiation advantage over established treatments.
- Commercial difficulty supporting a new HIV product with a narrow or uncertain therapeutic margin.
Alovudine’s development history resembles that of other early nucleoside analogues that showed strong in vitro activity but failed to achieve an acceptable long-term clinical profile. The modern HIV market places particular value on low toxicity, high genetic barriers to resistance, limited drug-drug interactions, and once-daily fixed-dose combinations.
What is the FDA regulatory status of alovudine?
Alovudine has no FDA approval and does not appear in the FDA Orange Book as an approved active ingredient or approved product. The FDA’s Orange Book lists approved drug products and applicable patent or exclusivity information. It does not identify alovudine as an approved HIV treatment. (U.S. Food and Drug Administration, 2025a)
No FDA exclusivity period, new chemical entity exclusivity period, pediatric exclusivity period, or approval-based regulatory protection is associated with alovudine.
| FDA regulatory category | Alovudine status |
|---|---|
| Approved new drug application | None identified |
| Abbreviated new drug application reference product | None |
| Orange Book listing | None |
| NCE exclusivity | None |
| Orphan-drug exclusivity | None identified |
| Pediatric exclusivity | None |
| FDA-approved indication | None |
What patents protect alovudine?
No active Orange Book patent estate protects an approved alovudine product because no alovudine product has FDA approval. Historical patent filings may have covered the compound, stereochemistry, pharmaceutical compositions, methods of treatment, or synthetic processes, but those rights would generally be subject to the 20-year patent term measured from the earliest effective nonprovisional filing date in the applicable jurisdiction.
The commercial significance of any original alovudine composition patent is therefore limited. Alovudine entered development many years ago, and any foundational patent rights would be expected to have expired or to be close to expiration, subject to jurisdiction-specific prosecution history, patent-term adjustment, patent-term extension, and claim scope.
Formulation and method-of-use protection
No current public evidence establishes an enforceable commercial formulation patent covering an approved alovudine product. Historical formulation patents, if any, would not create meaningful market protection without an approved product and an active commercialization program.
Potential historical claims could have included:
- Oral tablets or capsules containing alovudine.
- Combination therapy with other antiretroviral agents.
- Dosing methods for treatment-experienced HIV patients.
- Treatment of HIV strains resistant to other reverse transcriptase inhibitors.
- Pharmaceutical compositions using particular excipients or salt forms.
- Synthetic methods for producing fluorinated nucleoside intermediates.
These categories would not by themselves support a current market unless a new formulation or use produced clinically meaningful differentiation and obtained new regulatory protection.
Are there Paragraph IV challenges or generic entry risks?
No meaningful Paragraph IV litigation risk is visible because alovudine has no approved reference-listed drug in the United States. A Paragraph IV certification applies to an abbreviated new drug application referencing an FDA-approved product with listed patents. Without an Orange Book reference product, a conventional generic-entry pathway does not exist.
The relevant competitive risk is not generic erosion. It is substitution by approved, low-cost or highly effective HIV regimens, including generic versions of older nucleoside reverse transcriptase inhibitors.
| Entry issue | Assessment |
|---|---|
| Paragraph IV challenge | No material public record identified |
| ANDA pathway | No reference-listed alovudine product |
| Generic competition | Indirect, from alternative HIV drugs |
| Biosimilar competition | Not applicable |
| Patent cliff | No commercial alovudine cliff |
| Litigation exposure | No active branded-product litigation identified |
How does alovudine compare with current HIV treatments?
Alovudine would enter a market dominated by combination regimens containing integrase strand transfer inhibitors. Current treatment guidelines favor agents such as dolutegravir and bictegravir in combination with tenofovir, emtricitabine, or lamivudine. These products have stronger clinical positioning, established manufacturing infrastructure, extensive safety data, and broad guideline adoption. (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024)
| Product class | Representative agents | Competitive position versus alovudine |
|---|---|---|
| Integrase inhibitor combinations | Bictegravir, dolutegravir | Major first-line standard |
| Tenofovir-based NRTIs | Tenofovir disoproxil fumarate, tenofovir alafenamide | Broad use and established supply |
| Cytidine analogues | Emtricitabine, lamivudine | Common fixed-dose combination partners |
| Older thymidine analogues | Zidovudine | Generic, clinically established, but less favored |
| Alovudine | FLT, MIV-310 | No approved or commercial position |
Alovudine would require a clear advantage in resistance coverage, tolerability, dosing, or activity against treatment-refractory infection to justify redevelopment. Historical antiviral potency alone would not support premium pricing or guideline adoption.
What is the market projection for alovudine?
The base-case market projection is zero commercial revenue through the medium term. No approved product, active sponsor, regulatory filing, or late-stage trial supports a conventional launch forecast.
Base-case projection
| Period | Expected status | Revenue outlook |
|---|---|---|
| Current period | Discontinued investigational compound | No product revenue |
| 1 to 3 years | No public evidence of restart | Zero or immaterial |
| 3 to 5 years | Restart would require new sponsor and clinical package | Highly speculative |
| Beyond 5 years | Possible redevelopment only with new differentiation | Not forecastable on current evidence |
A redevelopment scenario would require:
- A new formulation or delivery system.
- A substantially improved safety profile.
- Evidence of activity against resistant HIV.
- Compatibility with a modern fixed-dose combination.
- A clinical strategy addressing treatment-experienced patients or another underserved population.
- New composition, formulation, or method-of-use intellectual property.
Even under a successful redevelopment scenario, the addressable market would be constrained by the availability of generic antiretrovirals and highly effective branded integrase inhibitor regimens. A niche market could exist in multidrug-resistant HIV, but this would require clinical evidence that alovudine retains activity against relevant resistant strains without reproducing its historical toxicity limitations.
Which companies are challenging or developing alovudine?
No current public company appears to be conducting a commercial alovudine program. Medivir is the company most closely associated with historical development of MIV-310. Public pipeline materials and historical corporate disclosures do not support a current licensing, co-development, or commercialization agreement for alovudine.
There is no identified active licensing deal comparable to the major HIV partnerships involving Gilead Sciences, ViiV Healthcare, Merck, or Bristol Myers Squibb.
What manufacturing and intellectual property barriers exist?
Manufacturing would not be the primary commercial barrier. As a small-molecule nucleoside analogue, alovudine could theoretically be manufactured through conventional chemical synthesis and oral solid-dose processes. The more significant issues are:
- Control of fluorinated nucleoside intermediates.
- Stereochemical purity.
- Impurity qualification.
- Stability and solid-state characterization.
- Scale-up economics.
- Demonstration of a clinically acceptable exposure range.
- New intellectual property sufficient to support investment.
Any new patent value would likely depend on a differentiated formulation, combination product, manufacturing process, or treatment method. A simple return to the historical compound would face weak exclusivity prospects and extensive competition.
Key Takeaways
- Alovudine is an investigational HIV nucleoside reverse transcriptase inhibitor, also known as FLT and MIV-310.
- Historical clinical development did not produce an approved product.
- No FDA approval, Orange Book listing, regulatory exclusivity, or commercial launch exists.
- Development was limited by safety and competitive positioning concerns.
- No material Paragraph IV, biosimilar, or branded-product litigation risk is apparent.
- Any foundational patent rights would be expected to have expired or lost practical commercial value.
- The current market projection is zero meaningful revenue.
- Redevelopment would require a new sponsor, improved safety, a differentiated formulation or use, and evidence against modern HIV treatment standards.
FAQs
Could alovudine be revived for multidrug-resistant HIV?
Only a new clinical program could establish that opportunity. Historical antiviral activity would not be sufficient without contemporary resistance, safety, and combination-treatment data.
Is alovudine available as a generic HIV medicine?
No. There is no FDA-approved alovudine reference product and no established U.S. generic product.
Does alovudine have biosimilar competition?
No. Alovudine is a chemically synthesized small molecule, not a biologic. Biosimilar law does not apply.
Could a new alovudine formulation receive patent protection?
A new formulation, salt, combination, manufacturing process, or method of use could potentially support patent claims if it met applicable novelty, inventive-step, and enablement requirements. Existing historical compound claims would provide limited protection.
What would make alovudine commercially viable?
A viable program would need a materially better safety profile, demonstrated activity against resistant HIV, a practical once-daily or long-acting delivery system, and a clinical niche not adequately served by current integrase inhibitor-based regimens.
References
National Center for Biotechnology Information. (n.d.). PubChem compound summary: Alovudine. PubChem. https://pubchem.ncbi.nlm.nih.gov/
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines
U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2025b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
More… ↓
